Ariyanachi K¹, Lakshmi Jyothi Tadi²*, Supriya Garapati³ and Pravin Pissude⁴

¹Assistant Professor, Department of Anatomy, All India Institute of Medical Sciences, Bibinagar, India
²Additional Professor/Covid Nodal Officer, Department of Microbiology, All India Institute of Medical Sciences, Bibinagar, India
³Associate Professor, Department of Anatomy, All India Institute Of Medical Sciences, Bibinagar, India
⁴Associate Professor, Department of Community Medicine, ESIC Medical College And Hospital, Hyderabad, India

*Corresponding Author: Lakshmi Jyothi Tadi, Additional Professor/Covid Nodal Officer, Department of Microbiology, All India Institute of Medical Sciences, Bibinagar, India.

Received: August 21,2021; Published: September 20, 2021

Abstract

Introduction: The novel SARS CoV2 coronavirus is believed to have emerged from bats in Wuhan in 2019 last yearAs of July 8, 2021, 20 vaccines worldwide have been licensed; 96 vaccines are in human clinical trials, 32 of which have entered the final stage of testing. VLP proved to be a promising alternative to soluble antigens. Because they have the conformation and composition of natural viruses, their shape, size, repeated antigen structure and geometry will trigger stronger humoral and cellular immune responses. Plants have a complex mechanism for eukaryotic protein production and also support the amplification of a large number of plant-specific viruses.

Method: 35 articles from Medline, Embase, Google Scholar, Scopus. PubMed were reviewed using the key words SARS CoV-2 plant-based vaccines.

Review: Virus-like particles (VLPs) are self-assembling structures derived from viral antigens, which mimic the natural structure of viruses but lack the viral genome. VLPs are similar in size and shape to real coronaviruses, but they lack nucleic acid and are therefore not infectious. The Phase 1 trial of Medicago's plant virus-like particles started in July 2020, involving 180 healthy volunteers aged 1855. All preparations are well tolerated, and adverse events after vaccination are usually mild to moderate. British American Tobacco, through its US biotechnology subsidiary Kentucky Bioprocessing (KBP), is developing a potential COVID19 vaccine and is currently undergoing preclinical testing. Using its plant-based Fast Pharming® system, iBio, a biotechnology innovator and biologics contract manufacturing organization, reported on its progress in the development of the second-generation vaccine candidate subunit IBIO202, which aims to prevent SARSCoV2 infection.

Conclusion: Now is the time to explore the true potential of plant-based vaccines,  proven technologies that have the potential to play an important role in promoting global health.

Keywords: SARS-CoV-2; Pandemic; Plant-Based Vaccines; Virus Like Particles; Covid-19

References

1. Ahmad T., et al. “Coronavirus Disease 2019 (COVID-19) pandemic and economic impact”. Pakistan Journal of Medical Sciences Quarterly 36 (COVID19-S4): S73-S78.
2. , et al. “Coronavirus disease 2019-COVID-19”. Clinical Microbiology Review 33 (2020): 10.1128/CMR.00028-20.
3. https://www.cdc.gov/flu/pandemic-resources/1918-commemoration/1918-pandemic-history.htm
4. “Spotlight on COVID-19: Vaccine development” (2020).
5. de Wit Emmie., et al. “SARS and MERS: recent insights into emerging coronaviruses”. Nature Reviews Microbiology 8 (2016): 523-534.
6. Burki Talha. “CEPI: preparing for the worst”. The Lancet Infectious Diseases3 (2017): 265-266.
7. Funk Colin D., et al. “Target Product Profile Analysis of COVID-19 Vaccines in Phase III Clinical Trials and Beyond: An Early 2021 Perspective”. Viruses3 (2021): 418.
8. Braun Marion., et al. “Virus-like particles induce robust human T-helper cell responses”. European Journal of Immunology 42,2 (2012): 330-340.
9. Landry Nathalie., et al. “Influenza virus-like particle vaccines made in Nicotiana benthamiana elicit durable, poly-functional and cross-reactive T cell responses to influenza HA antigens”. Clinical immunology (Orlando, Fla.) 2 (2014): 164-177.
10. Mohsen Mona O., et al. “Interaction of Viral Capsid-Derived Virus-Like Particles (VLPs) with the Innate Immune System”. Vaccines3 (2018): 37.
11. Hiatt A., et al. “Production of antibodies in transgenic plants”. Nature6245 (1989): 76-78.
12. Shim Byoung-Shik., et al. “Plant factory: new resource for the productivity and diversity of human and veterinary vaccines”. Clinical and Experimental Vaccine Research2 (2019): 136-139.
13. Laere Erna., et al. “Plant-Based Vaccines: Production and Challenges”. Journal of Botany, Hindawi Limited, (2016): 1-11.
14. Naderi S., et al. “Overview of plant-based vaccines”. Research Journal of Fisheries and Hydrobiology 10 (2015): 275-289.
15. Uthaya Kumar A., et al. “Current updates and research on plant-based vaccines for coronavirus disease 2019”. Clinical and Experimental Vaccine Research 1 (2021): 13-23.
16. Krenek Pavel., et al. “Transient plant transformation mediated by Agrobacterium tumefaciens: Principles, methods and applications”. Biotechnology Advances6 (2015): 1024-1042.
17. Rosales-Mendoza, S., et al. “What Does Plant Based Vaccine Technology Offer to the Fight against COVID-19?”. Vaccines 8 (2020): 183.
18. Ward BJ., et al. “Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19”. Nature Medicine 27 (2021) 1071-1078.
19. https://www.bloomberg.com/news/articles/2020-05-15/cigarette-maker-s-coronavirus-vaccine-poised-for-human-tests
20. Palca J. “Tobacco Plants Contribute Key Ingredient For COVID-19”. Vaccine (2020).
21. https://www.ibioinc.com/therapeutics-and-vaccines
22. , et al. “Engineering, production and characterization of Spike and Nucleocapsid structural proteins of SARS-CoV-2 in Nicotiana benthamiana as vaccine candidates against COVID-19”. bioRxiv (2020).

Citation

Citation: Lakshmi Jyothi Tadi., et al. “Plant-based Vaccines for SARS-CoV-2 Novel Corona Virus - A Review”. Acta Scientific Women's Health 3.10 (2021): 15-20.

Copyright

Copyright: © 2021 Lakshmi Jyothi Tadi., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.